key: cord-0974278-h1d63xhl
authors: Tesoriero, James M.; Patterson, Wendy; Daskalakis, Demetre; Chicoine, Joyce; Morne, Johanne; Braunstein, Sarah; Rajulu, Deepa T.; Rosenberg, Eli
title: Notes from the Field: COVID-19 Vaccination Among Persons Living with Diagnosed HIV Infection — New York, October 2021
date: 2022-02-04
journal: MMWR Morb Mortal Wkly Rep
DOI: 10.15585/mmwr.mm7105a4
sha: b82f95aa094a999c3ab3be7d053afcf66af68deb
doc_id: 974278
cord_uid: h1d63xhl

nan

Persons were categorized as having received either a single dose of the Food and Drug Administration-authorized or -approved Ad.26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine or 2 doses of the BNT162b2 (Pfizer BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccines ≥14 days before October 24, 2021; only the first of a 2-dose series vaccine (Pfizer-BioNTech or Moderna); or having no matching vaccine record. ¶ Booster and additional doses were not considered in this analysis. Consultation with the New York State Department of Health Institutional Review Board indicated that this work constitutes public health surveillance. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.** Among 101,205 PLWDH included in the analysis, † † 64,278 (63.5%) had received either a single dose of Janssen vaccine or 2 doses of Pfizer-BioNTech or Moderna vaccine, 4,349 (4.3%) had received only 1 dose of Pfizer-BioNTech or Moderna vaccines, and 32,578 (32.2%) were unvaccinated (Table) .

Receipt of either a single dose of Janssen vaccine or 2 doses of Pfizer-BioNTech or Moderna vaccine increased with age, including 71.4% of PLWDH aged ≥65 years and 54.3% of those aged 18-49 years. Coverage was higher among men (64.8%) than women (60.5%), and among persons who identified as nonbinary or nonconforming (58.1%). Among racial/ ethnic groups, coverage was highest among non-Hispanic White PLWDH (70.8%), and lowest among non-Hispanic Black (58.6%) and American Indian or Alaska Native persons (58.4%). Coverage was substantially lower among PLWDH who were not virally suppressed § § at last test in 2020 (38.1%) compared with those who were (72.0%), and among those with no surveillance-based evidence of HIV care in 2020 (29.1%) than among those receiving care (69.2%). ¶ This study found that COVID-19 vaccination coverage among PLWDH overall (63.5%) was lower than that in the general adult New York population (75.0%). ¶ ¶ Differences in demographic composition between PLWDH and the general population might partly explain lower coverage; however, coverage was <75% across all examined PLWDH subgroups. Unmeasured factors, including socioeconomic status, might further explain the lower COVID-19 vaccination coverage among PLWDH.

Members of non-Hispanic Black and Hispanic communities are more likely to acquire SARS-CoV-2 and experience severe COVID-19-related outcomes than are those of other non-Hispanic and White communities (5, 6) . Gaps in vaccination coverage could thus serve to amplify disparities in COVID-19 outcomes among PLWDH. Addressing the large disparity in vaccination coverage by HIV care and viral suppression status is of particular importance, given the increased likelihood of severe ¶ ¶ https://coronavirus.health.ny.gov/covid-19-breakthrough-data (Accessed October 24, 2021).

COVID-19-related outcomes among PLWDH who experience immunocompromising conditions and considering the specific recommendation for additional doses for this group (2) . In addition to primary vaccination coverage, ensuring that PLWDH receive booster doses is critically important moving forward.*** Including COVID-19 vaccination in HIV-related service delivery might be effective at reducing disparities in vaccination coverage among PLWDH. For example, incorporating COVID-19 vaccination into existing HIV Data to Care † † † programming might help increase vaccination rates among PLWDH being relinked to HIV care. Similarly, leveraging HIV providers serving communities of color and sexual minority populations to promote COVID-19 vaccination could help to mitigate racial/ethnic and gender-based disparities in vaccination coverage. *** https://www.cdc.gov/media/releases/2021/p1021-covid-booster.html (Accessed November 16, 2021). † † † https://wwwdev.cdc.gov/hiv/effective-interventions/treat/data-to-care/index. html?Sort=Title%3A%3Aasc&Intervention%20Name=Data%20to%20 CareName=Data%20to%20Care (Accessed November 17, 2021).

COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State

US Department of Health and Human Services, CDC; 2021

New COVID-19 cases and hospitalizations among adults, by vaccination status

COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis-California

Hospitalization and mortality among black patients and white patients with Covid-19

Assessing racial and ethnic disparities using a COVID-19 outcomes continuum for New York State

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.